Group 1 - The company, CaiNa Co., Ltd. (301122), reported that as of January 30, 2026, the number of shareholders is 6,957 [1]

Core Viewpoint - The company has approved the acquisition of a 70% stake in Jiangxi Fenglin Medical Technology Co., Ltd. for RMB 21 million, which will make Jiangxi Fenglin a subsidiary included in the company's consolidated financial statements [2]. Group 1 - The company held its 18th meeting of the third board of directors on December 22, 2025, where the investment acquisition proposal was approved [2]. - The acquisition will result in Jiangxi Fenglin becoming a controlling subsidiary of the company [2]. - The company has received the change registration certificate and shareholder register from Jiangxi United Registration and Settlement Co., Ltd., confirming the completion of the equity change registration [2].

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of 88.70% to 92.47% compared to the previous year, with net profit attributed to shareholders estimated between 4 million to 6 million yuan [1] Group 1: Financial Performance - The projected net profit for 2025 is between 4 million to 6 million yuan, indicating a substantial year-on-year decrease [1] - The net profit excluding non-recurring losses is expected to be between -12 million to -7 million yuan [1] Group 2: Factors Affecting Performance - The decline in performance is primarily due to the impact of the U.S. FDA import warnings and increased tariffs, which have altered the company's product sales structure and reduced overall gross profit margins [1] - The company is accelerating the construction and production of its facility in Cambodia to adapt to external environmental changes, which has led to increased fixed costs and initial production inefficiencies [1] - Additional costs have been incurred for the registration and certification of new products as part of the company's business layout strategy [1] - The company has recognized impairment losses on certain assets based on prudence principles in accordance with accounting standards [1]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 4 million to 6 million yuan, which represents a year-on-year decrease of 88.70% to 92.47% [1] Group 1 - The decline in net profit is attributed to ongoing impacts from the U.S. Food and Drug Administration (FDA) import warnings and increased tariffs imposed by the U.S. [1] - Changes in the company's product sales structure have occurred as a result of these external factors, leading to a decrease in the overall gross profit margin of the products [1]

关于对外投资收购股权进展暨完成 股权变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301122 证券简称：采纳股份 公告编号：2026-005 采纳科技股份有限公司 采纳科技股份有限公司董事会 一、股权收购概述 2025 年 12 月 22 日，采纳科技股份有限公司（以下简称"公司"）召开第 三届董事会第十八次会议，审议通过了《关于对外投资收购股权的议案》，同 意公司以人民币 2,100 万元整收购薛利繁持有的江西丰临医疗科技股份有限公 司（以下简称"江西丰临"）70%股权。交易完成后，江西丰临将成为公司的控 股子公司，纳入公司合并报表范围。具体内容详见公司 2025 年 12 月 23 日披露 于巨潮资讯网（http://www.cninfo.com.cn）的《关于对外投资收购股权的公 告》，公告编号：2025-098。 二、交易进展情况 近日，公司收到江西联合登记结算有限公司出具的《变更登记凭证》和 《非上市股份有限公司股东名册》，江西丰临已完成股权变更登记。变更后的 江西丰临股权结构情况如下： | 序号 | 股东名称 | 持股 ...

证券代码：301122 证券简称：采纳股份 公告编号：2026-006 采纳科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 单位：万元 本次业绩预告相关数据为公司财务部门初步测算的结果，未经会计师事务 所审计。公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会 计师事务所在本次业绩预告方面不存在重大分歧。 三、业绩变动原因说明 报告期内，影响公司业绩变动的主要原因： 1、报告期内，受到美国食品药品监督管理局（美国 FDA）进口警示以及 美国加征关税等因素的持续影响，公司的产品销售结构发生变化，导致产品综 合毛利率有所下滑。 2、为了积极应对外部环境变化，公司加快推进柬埔寨生产基地的建设和 投产。截至 2025 年底，柬埔寨工厂已实现部分投产，投产初期生产效率尚在 爬坡阶段，而固定成本已显著增加，对当期利润造成 ...

证券代码：301122 证券简称：采纳股份 公告编号：2026-004 采纳科技股份有限公司 关于公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"或"采纳股份"）于近日收到国 家知识产权局颁发的专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 一种交换针护帽的 自动塞棉机的棉花 上料机构 | 实用新型 | ZL 202423097188.4 | 采纳股份 | 2026 年 01 月 20 日 | | 2 | 针头收纳盒 | 外观设计 | ZL | 采纳股份 | 2026 年 01 月 | | | | | 202530258058.5 | | 20 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, but benefits from its overseas sales and the depreciation of the RMB [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue sources for Canar Medical are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of December 31, the number of shareholders is 7,184, a decrease of 3.12% from the previous period, while the average circulating shares per person increased by 3.22% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On January 13, the stock price of Canar Medical fell by 0.62%, with a trading volume of 120 million yuan and a turnover rate of 5.46%, resulting in a total market capitalization of 3.549 billion yuan [1]. - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. Group 4: Technical Analysis - The average trading cost of the stock is 27.99 yuan, with recent interest in the stock leading to increased concentration of holdings. The current stock price is near a resistance level of 29.73 yuan, indicating potential for a price correction if it does not break through this level [6].

Core Viewpoint - The company has adopted a share award plan aimed at recognizing contributions from eligible participants and providing incentives to retain talent for its operations and development [1] Group 1 - The share award plan will be effective for 10 years from the date of adoption, which is January 12, 2026 [1] - The plan will be funded solely by existing shares and will not involve the issuance of any new shares [1] - The objectives of the share award plan include attracting suitable talent for the company's further development [1]

Core Viewpoint - The company has adopted a share award plan aimed at recognizing contributions from eligible participants and providing incentives to retain talent for its operations and development [1] Group 1 - The share award plan will be effective for 10 years from the adoption date of January 12, 2026 [1] - The plan will be funded solely by existing shares and will not involve the issuance of any new shares [1] - The objectives of the plan include attracting suitable talent for the company's further development [1]